Business Standard

Dr Reddy's Lab rises 2.3%

Read more on:    Nordic Bioscience | Dr Reddys Lab
Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

Sensex, Nifty retreat from record high levels

Sensex touched its all-time high of 22,875.17 and the broader Nifty kissed 6,861.60 figure for first time

Cardamom up 0.7% on strong demand

Spice for delivery in June gained 0.38%

Palm oil down 0.3% on subdued demand

Oil for delivery in May traded lower by 0.15%

Natco extends gains on US court ruling over generic Copaxone

US Supreme Court ruling paved the way to launch generic version of Teva's Copaxone

Shasun Pharma zooms 40% in three days ahead of board meeting

The board is scheduled to meet today to consider issuing convertible warrants/equity shares on a preferential basis to the promoters.

Back to Top